ninety-six patients with de novo acute nonlymphocytic leukemia ( anll ) were randomized to receive either daunorubicin ( 50 mg/m2 , iv ) on days 1-3 ;
C0023467
acute nonlymphocytic leukemia
C0011015
daunorubicin